SLNO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Soleno Therapeutics Inc (SLNO) is not a good buy for a beginner investor with a long-term strategy at this time. The stock is facing significant negative catalysts, including insider selling, legal challenges, and weak technical indicators. Despite some positive analyst ratings and a strong gross margin, the company's financial performance has deteriorated, and the market sentiment remains negative. Given the investor's impatience and unwillingness to wait for optimal entry points, holding off on this investment is recommended.
The technical indicators for SLNO are bearish. The MACD histogram is negative (-0.321) and contracting, RSI_6 is at 27.958 (neutral zone), and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with S1 at 30.66 and S2 at 29.117, indicating potential further downside.
Analysts maintain a generally positive long-term outlook, with multiple firms rating the stock as a Buy or Outperform. The company has a strong gross margin of 99.06% and a promising commercial trajectory for its Vykat XR product.
The company is facing multiple class action lawsuits related to safety concerns with its DCCR drug, which has significantly impacted investor sentiment. Insider selling has increased by 1314.42% over the last month, and there are no significant hedge fund trading trends. The stock's financial performance in Q4 2025 showed a sharp decline in net income (-176.71% YoY) and EPS (-156.69% YoY).
In Q4 2025, revenue remained flat YoY at $91.73 million. However, net income dropped significantly to $42.94 million (-176.71% YoY), and EPS fell to 0.72 (-156.69% YoY). Despite a strong gross margin of 99.06%, the financial performance indicates declining profitability.
Analysts have lowered price targets recently, with Oppenheimer reducing its target to $80 from $110 and H.C. Wainwright lowering it to $100 from $120. However, they maintain Buy or Outperform ratings, citing a solid commercial outlook and expected revenue growth in FY26.
